Abstract
The relationship between theCYP2D6 genotype and the steady state plasma levels of nortriptyline (NT), its main active metabolite 10-hydroxynortriptyline (10-OH-NT) and the NT/10-OH-NT ratio were studied in 21 Caucasian depressed patients treated with 100–150 mg NT daily. The patients had participated in a previously published study investigating the role of NT and 10-OH-NT for the therapeutic effect of NT, and the plasma level data were from that study. In the present follow-up study, the patients were genotyped with respect to the polymorphicCYP2D6 by allelespecific PCR amplification andEcoRIRFLP. One poor metabolizer (PM) was identified and she had the highest plasma concentration of NT. Among the 20 extensive metabolizers (EM), the genotype (homozygous versus heterozygous EM) alone was not found to explain the variance in dose-corrected NT concentrations, but contributed significantly when gender was also taken into account. Together, these factors accounted for 59% of the variability in NT levels. Female patients had higher plasma levels of NT than male patients. 10-OH-NT levels were influenced by genotype, and NT/10-OH-NT ratio by genotype and gender. The present follow-up study confirms a relationship between theCYP2D6 genotype and the plasma levels of NT and its active metabolite. Identification of PM by genotyping should be of value for the prediction of the plasma levels and, consequently, the lower than average dose of NT required for optimal therapy. Also among EM, the genotype contributes to the variability in NT and 10-OH-NT levels but alone is of limited practical value for the prediction of optimal dosage.
Similar content being viewed by others
References
Alexanderson B, Borgå O (1973) Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses. Eur J Clin Pharmacol 5:174–180
Alexanderson B, Evans DAP, Sjöqvist F (1969) Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 4:764–768
Alexanderson B, Borgaå O, Alván G (1973) The availability of orally administered nortriptyline. Eur J Clin Pharmacol 5:181–185
Åsberg M, Evans DAP, Sjöqvist F (1971a) Genetic control of nortriptyline kinetics in man. A study of relatives of propositi with high plasma concentrations. J Med Genet 8:129–135
Åsberg M, Cronholm B, Sjöqvist F, Tuck D (1971b) Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 3:331–334
Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz H-U, Sjöqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27:1673–1677
Bertilsson L, Mellström B, Sjöqvist F, Mårtensson B, Åsberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet i: 560–561
Bertilsson L, Åsberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7:478–480
Bertilsson L, Dahl M-L, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63
Borgå O, Palmér L, Sjöqvist F, Holmstedt B (1973) Mass fragmentography used in quantitative analysis of drugs and endogenous compounds in biological fluids. In: Pharmacology and the future of man. Proceedings of the 5th International Congress on Pharmacology, vol. III. S. Karger AG, Basel, pp 56–68
Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, Baettig D, Baumann P (1992) Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 52:350–358
Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles ofCYP2D6 in a European population. DNA Cell Biol 10:545–558
Brøsen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K (1994) CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 47:221–225
Dahl M-L, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12–17
Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516–520
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) DefectiveN-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187
Evert B, Griese E-U, Eichelbaum M (1994a) Cloning and sequencing of a new non-functionalCYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 4:271–274
Evert B, Griese E-U, Eichelbaum M (1994b) A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedeberg's Arch Pharmacol 350:434–439
Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48:943–950
Gram LF (1977) Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 2:237–251
Gram LF, Brøsen K, Kragh-Sørensen P, Christensen P (1989) Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 11:508–514
Hammer W, Sjöqvist F (1967) Plasma level of monomethylated antidepressants during treatment with imipramine-like compounds. Life Sci 6:1895–1903
Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222–239
Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529–532
Jerling M, Merlé Y, Mentré F, Mallet A (1994) Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 — an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 38:453–462
Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825–11829
Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii:584–586
Mellström B, Bertilsson L, Säwe J, Schulz H-U, Sjöqvist F (1981) E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30:189–193
Nordin C, Siwers B, Benitez J, Bertilsson L (1985a) Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients-relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 19:832–835
Nordin C, bertilsson L, Siwers B (1985b) CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Br J Clin Pharmacol 20:411–413
Nordin C, Bertilsson L, Siwers B (1987) Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. Clin Pharmacol Ther 42:10–19
Nordin C, Bertilsson L, Dahl M-L, Resul B, Toresson G, Sjöqvist F (1991) Treatment of depression with E-10-hydroxynortripty-line — a pilot study on biochemical effects and pharmacokinetics. Psychopharmacology 103:287–290
Prescorn SH, Jerkovich GS (1990) Central nervous system toxicity of tricyclic antidepressants: pharmacology, course, risk factors and role of therapeutic drug monitoring. J Clin Psychopharmacol 10:88–95
Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ (1977) Polymorphic hydroxylation of debrisoquine. Lancet ii:718
Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H (1984) Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin Pharmacol Ther 35:540–544
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dahl, M.L., Bertilsson, L. & Nordin, C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype. Psychopharmacology 123, 315–319 (1996). https://doi.org/10.1007/BF02246640
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246640